Hyperlipidemia management in diabetes: First line or supportive therapy?

Gupta, Rajeev; Misra, Anoop

doi:10.1016/j.dsx.2022.102470

Cited by 5 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because some pathological diseases such as diabetes [11], epilepsy [12], alcoholism [13] and heart disease [14] are more common among people with hyperlipidemia. The authors conclude that hyperlipidemia may be a common strand that binds adhesive capsules to these pathologies.…”

Section: Resultsmentioning

confidence: 99%

Evaluation of serological factors in 29 patients with frozen shoulder, a cohort study

Rouhani

Parish

Dashti

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Frozen Shoulder is a painful and debilitating illness that affects 2 to 5% of the general population and up to 20% of those with diabetes, characterized with significant shoulder pain and reduced mobility, resulting in loss of passive and active movements in all directions in the first stage of frozen shoulder, which is sometimes mistaken with acute and subacute arthritis. We decided to conduct a study to evaluate serological factors in these patients. Methods The present investigation was a cohort study. First the target population and sample size were determined and the patients enrolled at the study were asked for their medical history, and then examined by a subspecialist physician to validate the diagnosis of frozen should. For all patients, a series of specific routine blood tests were requested and their shoulder range of motion and scores were recorded. Results A total of 29 patients with adhesive capsulitis with a mean age of 55.59 ± 9.57 and a mean BMI of 27.78 ± 4.59 were recruited, of whom 22 were female (75.9%) and 7 were male (24.1%). The mean levels of fasting blood glucose, (FBS) ESR and CRP were 100.61 ± 17.29 mg/dL, 16.89 ± 13.14 mm/h and 2.85 ± 6.88 mg/L, respectively. CRP levels were inversely associated with constant shoulder score (CSS). Conclusion The serum level of CRP might be a reliable biomarker for predicting the qualitative state of pain and range of motion in patients with adhesive capsulitis, as it is correlated with CSS. Trial registration: The present study was approved by the regional ethics committee of Tabriz University of Medical Sciences based on the Helsinki Declaration with the ethics code IR.TBZMED.REC.1398.990.

show abstract

Section: Resultsmentioning

confidence: 99%

Evaluation of serological factors in 29 patients with frozen shoulder, a cohort study

Rouhani

Parish

Dashti

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Fortunately, use of incretins improved the prognosis in people with diabetes 24,25 . Moreover, CAD is the leading cause of death among patients with T2DM 26,27 . MI is a type of CAD caused by complete obstruction of the coronary artery, and in CVOTs is also considered a MACE.…”

Section: Discussionmentioning

confidence: 99%

Effects of glucagon‐like peptide‐1 receptor agonists on major coronary events in patients with type 2 diabetes

Guo

Sang

Tang

et al. 2023

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aims: To perform a meta-analysis to assess the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on major coronary events, including myocardial infarction (MI), unstable angina and coronary revascularization, in patients with type 2 diabetes mellitus (T2DM). Materials and methods:We systematically searched the PubMed, CENTRAL, EMBASE and clinicaltrial.gov databases to seek eligible studies with a cardiovascular endpoint comparing GLP-1RAs with a placebo in T2DM patients. Odds ratio (ORs) and 95% confidence intervals (CIs) were calculated for the outcomes.Results: Nine studies, with a total of 64 236 patients, were included. GLP-1RA treatment reduced fatal and nonfatal MI by 8% (OR 0.92, 95% CI 0.86-0.99; P = 0.02, I 2 = 39%). The reduction reached 15% in human-based GLP-1RA-treated patients.Similarly, once-weekly GLP-1RA treatment reduced the risk of MI by 13%. In contrast, GLP-1RA treatment did not reduce the risk of hospitalization for unstable angina (OR 1.11, 95% CI 0.97-1.28; P = 0.13, I 2 = 21%). GLP-1RAs exhibited a tendency to lower the risk of coronary revascularization (OR 0.95, 95% CI 0.89-1.02; P = 0.15, I 2 = 22%), but without statistical significance. Human-based GLP-1RAs decreased the risk by 11%. Conclusions:In high-risk patients with T2DM, GLP-1RAs were associated with a decrease in MI, especially the human-based and once-weekly GLP-1RAs. No benefit was seen for hospitalization for unstable angina or coronary revascularization. Further research is urgently needed to ascertain improvements in coronary events.

show abstract

“…At the same time, fenofibrate can reduce the triglyceride level in diabetic patients. Combined with behavioral improvement and blood sugar control, it can reduce the risk of coronary heart disease death in diabetic patients (8). Therefore, treatment regimens for heart failure patients with diabetes should increase lipid metabolism regulation strategies to reduce patients' risk of poor prognosis.…”

Section: Discussionmentioning

confidence: 99%

Effect of fenofibrate on blood lipid, sICAM-1, ET-1 and prognosis in chronic heart failure patients complicated with diabetes

Liu¹,

Zhang²,

Zhou³

et al. 2023

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

Hyperlipidemia management in diabetes: First line or supportive therapy?

Cited by 5 publications

References 30 publications

Evaluation of serological factors in 29 patients with frozen shoulder, a cohort study

Evaluation of serological factors in 29 patients with frozen shoulder, a cohort study

Effects of glucagon‐like peptide‐1 receptor agonists on major coronary events in patients with type 2 diabetes

Effect of fenofibrate on blood lipid, sICAM-1, ET-1 and prognosis in chronic heart failure patients complicated with diabetes

Contact Info

Product

Resources

About